Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 15;11(1):27-37.
doi: 10.5009/gnl15502.

25 Years of Proton Pump Inhibitors: A Comprehensive Review

Daniel S Strand  1 , Daejin Kim  2 , David A Peura  1
Affiliations
Review

25 Years of Proton Pump Inhibitors: A Comprehensive Review

Daniel S Strand et al. Gut Liver. .

Abstract

Proton pump inhibitors (PPIs) were clinically introduced more than 25 years ago and have since proven to be invaluable, safe, and effective agents for the management of a variety of acid-related disorders. Although all members in this class act in a similar fashion, inhibiting active parietal cell acid secretion, there are slight differences among PPIs relating to their pharmacokinetic properties, metabolism, and Food and Drug Administration (FDA)-approved clinical indications. Nevertheless, each is effective in managing gastroesophageal reflux disease and uncomplicated or complicated peptic ulcer disease. Despite their overall efficacy, PPIs do have some limitations related to their short plasma half-lives and requirement for meal-associated dosing, which can lead to breakthrough symptoms in some individuals, especially at night. Longer-acting PPIs and technology to prolong conventional PPI activity have been developed to specifically address these limitations and may improve clinical outcomes.

Keywords: Indications; Pharmacokinetics; Proton pump inhibitors; Review; Risk.

PubMed Disclaimer

References

    1. Farley A, Wruble LD, Humphries TJ. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial: Raberprazole Study Group. Am J Gastroenterol. 2000;95:1894–1899. doi: 10.1111/j.1572-0241.2000.02233.x. - DOI - PubMed
    1. Huang JQ, Hunt RH. pH, healing rate and symptom relief in acid-related diseases. Yale J Biol Med. 1996;69:159–174. - PMC - PubMed
    1. U.S. Food and Drug Administration. Proton pump inhibitors: US Food and Drug Administration-approved indications and dosages for use in adults [Internet] Silver Spring: U.S. Food and Drug Administration; 2014. [cited 2016 Aug 31]. Available from: http://www.fda.gov/drugs.
    1. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798–1810. doi: 10.1053/gast.1997.v112.pm9178669. - DOI - PubMed
    1. Lassen AT. Acid-related disorders and use of antisecretory medication. Dan Med Bull. 2007;54:18–30. - PubMed

MeSH terms

Substances